Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS) by Delgado, D. et al.
                          Delgado, D., Canham, L., Cotterill, N., Cottrell, D., Drake, M. J., Inglis, K.,
... White, P. (2017). Protocol for a randomized, double blind, placebo
controlled, crossover trial of Melatonin for treatment of Nocturia in adults
with Multiple Sclerosis (MeNiMS). BMC Neurology, 17(1), 1-11. [63].
https://doi.org/10.1186/s12883-017-0845-y
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s12883-017-0845-y
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMC Neurology  at
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-017-0845-y. Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Delgado et al. BMC Neurology  (2017) 17:63 
DOI 10.1186/s12883-017-0845-ySTUDY PROTOCOL Open AccessProtocol for a randomized, double blind,
placebo controlled, crossover trial of
Melatonin for treatment of Nocturia in
adults with Multiple Sclerosis (MeNiMS)
D. Delgado1, L. Canham2,3, N. Cotterill1, D. Cottrell2, M. J. Drake1,3*, K. Inglis1, D. Owen1 and P. White4Abstract
Background: Nocturia (the symptom of needing to wake up to pass urine) is common in progressive Multiple
Sclerosis (MS) patients. Moderate-to-severe nocturia affects quality of life, can exacerbate fatigue and may affect
capacity to carry out daily activities.
Melatonin is a natural hormone regulating circadian cycles, released by the pineal gland at night-time, and
secretion is impaired in MS. Melatonin levels can be supplemented by administration in tablet form at bedtime.
The aim of this study is to evaluate the effect of melatonin on mean number of nocturia episodes per night in MS
patients. Secondary outcome measures will assess impact upon quality of life, urinated volumes, lower urinary tract
symptoms (LUTS), cognition, sleep quality and sleep disturbance of partners.
Methods: A randomized, double blind, placebo controlled, crossover trial consisting of two, six week treatment
phases (active drug melatonin 2 mg or placebo), with a 1 month wash-out period in between.
The primary outcome (change in nocturia episodes per night) in this two arm, two treatment, two period crossover
design, will be objectively measured using frequency volume charts (FVC) at baseline and following both treatment
phases. Questionnaires will be used to assess quality of life, sleep quality, safety and urinary tract symptoms.
Qualitative interviews of participants and partners will explore issues including quality of life, mechanisms of sleep
disturbance and impact of nocturia on partners.
Discussion: This study will evaluate whether melatonin reduces the frequency of nocturia episodes in MS patients, and
therefore whether ‘Circadin’ has the potential to reduce LUTS and fatigue, and improve cognition and overall quality of life.
Trial registration: (EudraCT reference) 2012–00418321 registered: 25/01/13. ISRCTN Registry: ISRCTN38687869
Keywords: Multiple Sclerosis, Nocturia, Melatonin, LUTS, CognitionBackground
Normal urinary function shows a circadian (day/night)
cycle, with reduced urine production and bladder excit-
ability during sleep. Nocturia is the symptom of need-
ing to wake up to pass urine. It is caused by increased
bladder excitability, impaired salt/fluid handling and
endocrine causes.* Correspondence: Marcus.Drake@bui.ac.uk
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(http://creativecommons.org/publicdomain/zeNocturia is common; overall prevalence of nocturia is
substantial, and progresses in severity with ageing [1].
Nocturia is highly prevalent in neurological disease. Mild
nocturia (1 episode per night) may be regarded as a
“nuisance” symptom, of minor importance. However, if
there are other reasons for sleep disturbance, as is
common in multiple sclerosis (MS) [2], the additional
episode of sleep disturbance from nocturia becomes
more important for the person affected.
Moderate-to-severe nocturia profoundly affects quality
of life as a consequence of fatigue, which results from
the shortening of overall sleep duration and disruptionle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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More importantly, severe nocturia is associated with
major health problems [3]. The condition is thus
important personally (impaired quality of life from
fatigue), economically (impaired function affecting
employment; for disabled or elderly people, need for
additional care and reduced ability to maintain inde-
pendent living at home) and clinically (association with
major health issues).
Standard treatment comprises controlling fluid intake,
timed diuretics, desmopressin, antimuscarinic drugs or
bedtime sedatives/miscellaneous compounds [4]. Nocturia
can be multifactorial, and a range of interventions is
needed to individualise treatment selection and have the
best chance of ameliorating symptoms. Current options
can have side effects- which are common with antimus-
carinics (dry mouth, constipation, swallowing difficulty,
cognitive impairment), and sedatives (confusion, sedation
hangover). Serious complications include; hyponatraemia
(salt depletion/dilution) with diuretics/desmopressin, and
acute retention of urine with antimuscarinics. Perceived
poor efficacy and the safety concerns mean that clinicians
may fail to evaluate fully or feel reluctant to instigate treat-
ment; as a consequence, even severe nocturia symptoms
may be left untreated.
Our conjecture is that nocturia signifies impaired cir-
cadian regulation, potentially mediated at 3 levels; (i)
bladder muscle excitability, (ii) renal urine output, (iii)
conscious response to bladder sensation. The concept
that nocturia represents a disruption of circadian control
of various body processes (bladder urine storage, kidney
urine production and brain response to urinary sensa-
tion) is evident. It shifts emphasis from organs to the in-
dividual person; thereby the treatment basis moves from
suppressing organ activity (antimuscarinics, antidiure-
tics, sedatives), towards restoration of deficient circadian
activity. This shift takes a holistic approach aiming to
restore normal function in the organism, rather than
suppressing abnormal function in individual organs; im-
proved function by restoration of the native hormone.
Melatonin is a natural hormone regulating circadian cy-
cles, released by the brain’s pineal gland at night-time,
and varying with sleep state. It reduces smooth muscle
activity including in the bladder [5]. Melatonin levels
can be supplemented by administration in tablet form
[6]; given at bedtime, it improves sleep quality. Litera-
ture review shows melatonin has been used for nocturia
in two small studies. In men with benign prostate en-
largements, a subgroup of patients who benefitted from
exogenous melatonin treatment (“nocturia responders”)
has been reported [7]. Melatonin has also been used for
nocturia in the elderly [6], for whom it was found to
have significant benefit in ameliorating symptom severity
and improving quality of life.MS is the commonest cause of acquired neurological
disability in young adults and is characterised by the
progressive inflammatory loss of myelin and neuronal
tissue in the central nervous system. In both the initial
Relapsing-Remitting Phase and subsequent Progressive
Phase of MS urinary symptoms are common, including
nocturia, along with sleep disturbance from other causes
(e.g. restless legs syndrome, anxiety). The impact upon
quality of life is substantial; fatigue leads to reduced cap-
acity to carry out daily activities, which is a particular
problem in a disabled patient group. Fatigue itself is the
most common symptom of Multiple Sclerosis and the
main disabling feature for many patients. There is an ab-
solute paucity of effective therapies for this severe symp-
tom which is considered to be multifactorial and greatly
exacerbated by all forms of sleep deprivation and dis-
turbance. Fatigue is well recognised as a key determinant
in a patient’s capacity to maintain occupation, independ-
ence and social participation.
Impaired melatonin secretion occurs in multiple
sclerosis [8, 9]. Melatonin may have anti-inflammatory
and neuroprotective effects [10–12], which are poten-
tially relevant when considering its use in MS. We
propose that exogenous administration of melatonin
may counteract symptom severity in nocturia, with
lower risk of adverse effects than current available agents.
Accordingly, the main hypothesis is that bedtime adminis-
tration of a 2 mg melatonin sustained-release tablet will
improve clinical nocturia with consequent benefit for
sleep quality and quality of life, in patients with
progressive MS.Study aims
The primary aim is to evaluate effect of melatonin on
mean number of nocturia episodes per night.
Secondary aims are to evaluate; 1) Improvement in
quality of life, 2) safety, 3) lower urinary tract symptoms
(LUTS), 4) total voided (urinated) volume and mean vol-
ume per void, 5) sleep quality and 6) sleep disturbance
of partners. A sub-group of volunteers will also partici-
pate in assessments of Cognition.Methods
Study design
This trial is a double-blind randomised placebo con-
trolled crossover clinical trial to compare sustained-
release melatonin (‘Circadin’ 2 mg) against placebo. A
run-in phase will be followed by two treatment phases
(active drug or placebo) of 6 weeks each separated by a
wash-out interval of 1 month.
The treatment phases will be 2 mg per night (taken at
bedtime) of capsulated sustained-release melatonin
(‘Circadin’) or 1 placebo capsule per night, identical in
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double-blind randomized.
Return to baseline after washout between the two
treatment phases will be assessed with the International
Consultation on Incontinence-Nocturia (ICIQ-N) and
Cambridge Multiple Sclerosis Basic Score (CaMBS).
Study setting and participants
This trial will recruit multiple sclerosis patients from
North Bristol NHS Trust. Eligible subjects must be over
18 years of age with a confirmed neurological diagnosis
of MS and least 1 episode of nocturia (as defined by
International Continence Society criteria [13]) every
night. In addition female subjects of child-bearing poten-
tial must agree to use an effective method of contracep-
tion throughout the study.
Subjects will be excluded if they i) are pregnant, ii)
have a symptomatic urinary infection or iii) indwelling
catheter, iv) use prescription/non-prescription sleeping
tablets or Melatonin, v) use desmopressin or investiga-
tional medical compounds in the month preceding
randomization vi) take antimuscarinic or diuretic medi-
cation, unless used long-term prior to study (at least
3 months) and continued at same dosing regime
throughout the study, vii) have Diabetes mellitus or
Diabetes insipidus.
All subjects will provide informed written consent
prior to involvement in the study. The NRES Committee
South West – Exeter have approved the study protocol
(REC reference number: 12/SW/0322). A request for a
clinical trial authorisation was accepted by the UK
MHRA (reference; 18524/0222/001-0001). The study is
registered in the BioMed Central ISRCTN Registry
(http://www.isrctn.com/ISRCTN38687869).
Any protocol modifications that become necessary
during the course of the trial will be discussed with all
relevant parties in advance.
Planned interventions
Baseline clinical assessment
 Neurological diagnosis and medical history
 Medication review
 Dipstick urinalysis to screen for urinary tract
infection (specifically evaluating for presence of
nitrites)
 Nocturia assessment tool (ICIQ-N)
 Women of childbearing potential must have a
negative urinary pregnancy test at screening (before
the first study drug intake) & must agree to use a
reliable method of contraception from the screening
visit until 4 weeks after study drug discontinuation.
Acceptable methods of birth control during
participation in the study include: oralcontraceptives, patch contraceptives, injection
contraceptives, male condom with spermicide,
diaphragm or cervical cap with spermicide, vaginal
contraceptive ring, intrauterine device, surgical
sterilization (bilateral tubal ligation), vasectomised
partner(s) or total sexual abstinence.
 The MeNiMS co-ordinating centre will be notified if
a subject becomes pregnant during the study, or
changes her method of contraception
A woman is considered to be of childbearing potential
unless she meets one of the following criteria: Previous
bilateral salpingo-oophorectomy or hysterectomy, pre-
mature ovarian failure confirmed by a gynaecologist,
aged >50 years and not treated with any kind of hor-
mone replacement therapy for at least 2 years prior to
screening, with amenorrhea for at least 24 consecutive
months prior to screening, and a serum follicle stimulat-
ing hormone (FSH) level of >40 IU/L at Screening.
Outcome measures
Primary outcome measure: Reduction in nocturia epi-
sodes per night, derived from a frequency volume chart
(FVC). Analysis will be undertaken to assess the mean
reduction in mean nocturia episodes. Reduced episodes
of nocturia/night signifies improved sleep disturbance;
0.5/night fewer is clinically significant in older men [7];
this number may be different in MS, a condition in
which there can be diverse causes of sleep disturbance.
Secondary outcome measures;
1. Improved quality of life; assessed with the MS
Quality of Life Index (MSQLI) [14], a disease-
specific tool to capture comprehensive quality of life
dimensions, including: fatigue, urinary symptoms
and general function.
2. Safety. MS disease severity at three key trial stages
(before and at the end of each of the treatment
periods) will be catalogued by assessing the MS-
specific Expanded Disability Status Scale (EDSS)
[15], the only outcome rating for MS disability
accepted by Regulatory Authorities. Adverse events
including MS relapses will also be documented.
3. Urinary tract symptoms; response of LUTS to
melatonin treatment will be evaluated using tools of
the International Consultation on Incontinence
Questionnaire (ICIQ). ICIQ-MLUTS and ICIQ-
FLUTS are gender specific tools for assessing
severity and bother of all LUTS [16]. Nocturia-
specific tools are also available within ICIQ [17].
The ICIQ-N is a short tool, which will be used in
screening and at the end of the crossover washout
to catalogue subjective severity. Since the ICIQ-N
questions are present verbatim in ICIQ-MLUTS and
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the general LUTS tools at baseline and ends of the
treatment phases. ICIQ-NQoL is a nocturia-specific
quality of life tool which will be used throughout the
study.
4. Voided volume; the FVC will evaluate total
overnight voided volume (by the standardised
criteria [13]); mean voided volume will be derived by
dividing total nocturnal voided volume by the
number of nocturnal voids. Post void residual (PVR)
will be checked during clinical assessment, with
retesting during the study if clinically indicated.
5. Sleep quality; measured with the Pittsburgh Sleep
Quality Index (PSQI) [18].
6. Partner’s sleep disturbance; impact of nocturia on
bed-sharing partners is under-recognised. We will
seek permission from study subjects to approach
partners, in order to invite them to undertake
qualitative interview regarding impact of nocturia on
partners. This will be used to inform design of a
partner-specific tool (akin to that developed for
partners of men with prostate enlargement [19] for
subsequent nocturia research.
7. Cognition sub-study; performance on the minimal
assessment of cognitive function in MS (MACFIMS),
which is an objective, internationally validated tool
for specific evaluation of several key domains of
cognitive function specifically affected in MS [20]
and features the three key tests of the BICAMS
which is undergoing international validation as the
newest cognitive outcome measure for translational
inquiry.
Qualitative assessment
Qualitative Interviews will be undertaken and analysed
using standard thematic methods, to capture key issues
from the patient/partner perspective. Qualitative inter-
views will be carried out after the final treatment phase,
undertaking a thematic analysis to explore issues of
quality of life, mechanisms of sleep disturbance, coping
strategies, impact on partners, and aspects of participat-
ing in a study. Specific aims will be to;
 Explore the patients’ perspective of nocturia.
 Explore perceptions of the intervention on nocturia
and associated quality of life impact from patients’
perspective.
 Evaluate the validity of the ICIQ-NQoL in the MS
population.
 Where possible partners will also be interviewed on
the above perspectives to explore wider impact.
Semi structured interviews will be recorded and analysed
for emerging themes, with double coding of transcripts.Sufficient interviews will be undertaken to achieve satur-
ation of emerging themes. Qualitative interviews will be
carried out after the second treatment phase has been com-
pleted. Subjects will be able to opt out of participating in
the qualitative assessment; a separate consent for qualitative
assessment interview will be obtained. We will ask subjects
for permission to undertake qualitative assessment with
partners; if allowed to approach the partner, a separate con-
sent for qualitative assessment interview will be obtained
from the partner. The study flowchart is given in (Table 1).
Withdrawal criteria
A study subject will be discontinued from participation
in the study if:
 Any clinically significant Adverse Event (AE) as
evaluated by the PI, laboratory abnormality,
intercurrent illness, or other medical condition or
situation occurs such that continued participation in
the study would not be in the best interest of the
subject.
 The subject meets any exclusion criterion (either
newly developed or not previously recognized).
Subjects are free to withdraw from participation in the
study at any time upon request. Subjects who withdraw
from the study will be followed up clinically as part of
normal clinical care. Patients who withdraw as a conse-
quence of Adverse Events will be followed up by the
Study for 3 months and remain under clinical manage-
ment thereafter if indicated. Safety data will be collected
on any subject discontinued because of an AE or Serious
Adverse Event (SAE) for a period of 3 months. Every ef-
fort will be made to undertake protocol-specified safety
follow-up procedures under medical supervision until
the symptoms of any AE resolve or the subject’s condi-
tion becomes stable. If voluntary withdrawal occurs, the
subject will be asked to continue scheduled evaluations,
complete an end-of-study evaluation, and be given ap-
propriate care. All trial data to date will be held securely
as per study subjects completing the protocol.
Randomisation and enrolment procedure
Patients will be enrolled by invitation, if they fulfil all inclu-
sion criteria and no exclusion criteria. A randomisation
schedule will be generated by the website Randomization.-
com (http://www.randomization.com). Clinical trial mate-
rials will be packed and Qualified person (QP) certified by a
contracted NHS Pharmacy, according to the randomization
schedule (under Article 13 of EU directive 2001/20/EC).
The medication bottles and randomization schedule will be
shipped to the site pharmacy, following regulatory ap-
provals. The randomisation schedule will be strictly con-
trolled and remain in the pharmacy site file for emergency
Table 1 Study Flowchart
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pharmacy controlled allocation concealment. Medication
bottles will be dispensed in sequential number order, with
each subject receiving Period 1 and Period 2.
Unblinding during the trial will only be undertaken in
the event of a SAE or Suspected Unexpected SeriousAdverse Reaction (SUSAR), or disease progression,
under the authorization of the principal investigators.
Emergency unblinding will be managed by North Bristol
NHS Trust Pharmacy Department, according to stand-
ard operating procedure (CT/011). The study includes
three MS-specific Expanded Disability Status Scale
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ment period) to monitor disease severity. Interim ana-
lysis will evaluate outcomes of the first treatment period.
The analyses will provide the content of a blinded report
to the Trial Management Group (TMG). If issues of
safety emerge, the TMG will be empowered to request
unblinded data.
Interaction with other drugs
The subjects will not be permitted to use
 Sedative medications (CNS depressants). Taking
melatonin along with sedative medications might
cause excessive sleepiness. Sedative medications
include clonazepam (Klonopin), lorazepam (Ativan),
phenobarbital (Donnatal), zolpidem (Ambien), and
others. Patients will be instructed to discuss with the
trial co-ordinating office before starting such
medications.
Caution will be advised for the following;
 Birth control pills (Contraceptive drugs). Taking
melatonin along with birth control pills might
increase the effects and side effects of melatonin.
Effective methods of birth control for females of
child-bearing potential are an inclusion criterion of
the MeNiMS study; the trial co-ordinating office
records method of contraception on the Case Report
Form (CRF).
 Fluvoxamine (Luvox). Taking fluvoxamine (Luvox)
can increase the amount of melatonin that the body
absorbs. Taking melatonin along with fluvoxamine
(Luvox) might increase the effects and side effects of
melatonin. Patients will be instructed to discuss with
the trial co-ordinating office before starting
fluvoxamine.
 Medications for diabetes (Antidiabetes drugs).
Melatonin might increase blood sugar, and thereby
might decrease the effectiveness of diabetes
medications. The dose of diabetes medication might
need to be changed. Some medications used for
diabetes include glimepiride (Amaryl), glyburide
(DiaBeta, Glynase PresTab, Micronase), insulin,
pioglitazone (Actos), rosiglitazone (Avandia),
chlorpropamide (Diabinese), glipizide (Glucotrol),
tolbutamide (Orinase), and others.
 Medications that decrease immune system function
(Immunosuppressants). Melatonin might reduce the
efficacy of immunosuppression. The trial co-
ordinating office will discuss immunosuppression
therapy with relevant patients.
 Medications that slow blood clotting
(Anticoagulant/Antiplatelet drugs). Melatonin mightslow blood clotting. Taking melatonin along with
medications that also slow clotting might increase
the chances of bruising and bleeding. Some
medications that slow blood clotting include aspirin,
clopidogrel (Plavix), diclofenac (Voltaren, Cataflam,
others), ibuprofen (Advil, Motrin, others), naproxen
(Anaprox, Naprosyn, others), dalteparin (Fragmin),
enoxaparin (Lovenox), heparin, warfarin
(Coumadin), and others. The trial co-ordinating
office will discuss anticoagulation therapy with
relevant patients.
 Nifedipine GITS (Procardia XL). Taking melatonin
might decrease the effectiveness of nifedipine GITS
for lowering blood pressure.
 Verapamil (Calan, Covera, Isoptin, Verelan).
Verapamil (Calan, Covera, Isoptin, Verelan) can
increase how quickly the body metabolises
melatonin. Taking melatonin along with verapamil
(Calan, Covera, Isoptin, Verelan) might decrease the
effectiveness of melatonin.
Dispensing and accountability
Dispensing, checking and collection is according to
North Bristol NHS Trust Pharmacy standard operating
procedures (CT/008).
Site staff will count study drug back in at return clinic
visits, and remind the subject that they need to bring all
their study drug and packaging back with them.
Pharmacovigilance
Melatonin appears to cause very few side-effects in the
short term, up to three months, when healthy people
take it at low doses. A systematic review in 2006 looked
at safety with melatonin usage for secondary sleep
disturbances and sleep disorders accompanying sleep re-
striction [19]. The study concluded that melatonin is
safe with short term use.
Unwanted effects in some people, especially at high
doses (3 mg/day or more) may include: headaches, nausea,
next-day grogginess or irritability, hormone fluctuations,
vivid dreams or nightmares, gastrointestinal irritation, re-
duced blood flow and hypothermia. While no large, long-
term studies that might reveal side-effects have been
conducted, there do exist case reports about patients hav-
ing taken melatonin for months. Melatonin can cause
somnolence (drowsiness), and, therefore, caution should
be shown when driving, operating machinery, etc.
Definitions
Adverse Event (AE): any untoward medical occurrence in
a patient or clinical trial subject administered a medicinal
product and which does not necessarily have a causal rela-
tionship with this treatment. An AE can therefore be any
unfavourable and unintended sign (including an abnormal
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ciated with the use of an investigational medicinal product
(IMP), whether or not considered related to the IMP.
Adverse Reaction (AR): all untoward and unintended
responses to an IMP related to any dose administered.
All AEs judged by either the reporting investigator or
the sponsor as having reasonable causal relationship to a
medicinal product qualify as adverse reactions. The
expression “reasonable causal relationship” means to
convey in general that there is evidence or argument to
suggest a causal relationship.
Unexpected Adverse Reaction: an AR, the nature or
severity of which is not consistent with the applicable
product information (e.g., investigator’s brochure for an
unapproved investigational product or summary of prod-
uct characteristics (SmPC) for an authorised product).
When the outcome of the adverse reaction is not
consistent with the applicable product information this
adverse reaction should be considered as unexpected.
Side effects documented in the SmPC which occur in a
more severe form than anticipated are also considered
to be unexpected.
Serious Adverse Event (SAE) or Serious Adverse Reac-
tion: any untoward medical occurrence or effect that;
 Results in death
 Is life-threatening – refers to an event in which the
subject was at risk of death at the time of the event;
it does not refer to an event which hypothetically
might have caused death if it were more severe
 Requires hospitalization, or prolongation of existing
inpatients’ hospitalization
 Results in persistent or significant disability or
incapacity
 Results in a congenital anomaly or birth defect
Medical judgement should be exercised in deciding
whether an AE/AR is serious in other situations. Import-
ant AE/ARs that are not immediately life-threatening or
do not result in death or hospitalization but may jeop-
ardise the subject or may require intervention to prevent
one of the other outcomes listed in the definition above,
should also be considered serious.
Suspected Unexpected Serious Adverse Reaction (SUSAR):
any suspected adverse reaction related to an IMP that is both
unexpected and serious.
Causality
Most adverse events and adverse drug reactions that
occur in this trial, whether they are serious or not, will
be expected treatment-related toxicities due to the drugs
used in this trial. The assignment of the causality will be
made by the investigator responsible for the care of the
participant using the definitions in the table below. Ifany doubt about the causality exists the local investiga-
tor will notify the Chief Investigator.
Relationships
Unrelated. There is no evidence of any causal
relationship
Unlikely. There is little evidence to suggest there is a
causal relationship (e.g. the event did not occur within a
reasonable time after administration of the trial medica-
tion). There is another reasonable explanation for the
event (e.g. the participant’s clinical condition, other con-
comitant treatment).
Possible. There is some evidence to suggest a causal
relationship (e.g. because the event occurs within a rea-
sonable time after administration of the trial medica-
tion). However, the influence of other factors may have
contributed to the event (e.g. the participant’s clinical
condition, other concomitant treatments).
Probable. There is evidence to suggest a causal rela-
tionship and the influence of other factors is unlikely.
Definitely. There is clear evidence to suggest a causal
relationship and other possible contributing factors can
be ruled out.
Not assessable. There is insufficient or incomplete
evidence to make a clinical judgment of the causal
relationship.
Reporting procedures
Non serious AR/AEs All such toxicities, whether ex-
pected or not, will be recorded in the toxicity section of
the relevant case report form and sent to the trial coord-
ination centre within one month of the form being due.
Serious AR/AEs Fatal or life threatening SAEs and
SUSARs will be reported on the day that the local site is
aware of the event. The SAE form asks for nature of
event, date of onset, severity, corrective therapies given,
outcome and causality (i.e. unrelated, unlikely, possible,
probably, definitely). The responsible investigator will
sign the causality of the event. Additional information
will be sent within 5 days if the reaction has not resolved
at the time of reporting.
An SAE form will be faxed to the trial coordination
centre for all SAEs within 24 h. However, relapse and
death due to MS, and hospitalizations for elective treat-
ment of a pre-existing condition do not need reporting
as SAEs.
In the case of suspected unexpected serious adverse
reactions (SUSARs), the staff at the site will: Complete
the SAE case report form & send it immediately (within
24 h, preferably by fax), signed and dated to the trial co-
ordination centre together with relevant treatment forms
and anonymised copies of all relevant investigations.
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REC and the Sponsor of all SUSARs occurring during
the trial according to the following timelines; fatal and
life-threatening within 7 days of notification and non-life
threatening within 15 days. All investigators will be in-
formed of all SUSARs occurring throughout the trial.
Local investigators will report any SUSARs and/or SAEs
as required by their Local Research Ethics Committee
and/or Research & Development Office.
Subjects will have a safety follow-up at 2 – 4 weeks by
telephone call. If there has been an AE, the participant
will be followed up until the AE resolves, or resolves
with sequelae for a limit of 3 months and will remain
under clinical management as needed.
Loss to follow-up
Subjects lost to follow up will be contacted by telephone
call and subsequently through their general practitioner.
If they can be contacted, they will then be managed as
per withdrawals. Records relating to all patients lost to
follow up will be retained and archived according to the
overall study protocol.
Trial closure
The end of the crossover study will be defined as the
point at which all study subjects have completed the
data collection visits and follow up.
The trial will be closed prematurely if the TMG rec-
ommends it to the steering committee on the grounds
of safety or futility. Interim analysis will be undertaken
following the first treatment period. The analysis will
provide the content of a blinded report to the TMG,
which will consider safety/adverse effects, and assess the
possibility of futility. If issues of safety emerge, the TMG
will be empowered to request unblinded data. As it
deems necessary, the TMG will make recommendations
to the sponsor on further study conduct, including
continuing, terminating, or modifying the trial. Early ter-
mination will result if clinically significant unexpected
adverse effects are seen, or if the study is deemed futile,
or if the beneficial effect is so obvious that curtailment
can occur.
The Sponsor (Research & Innovation Department
North Bristol NHS Trust) will monitor the study to en-
sure compliance with Good Clinical Practice procedures.
Statistics and data analysis
Sample size is informed by (a) a previous study of mela-
tonin, which showed a reduction in nocturia episodes of
0.5 per night to be clinically significant [7], (b) compar-
able crossover investigations using melatonin in other
populations [21], (c) crossover trial methodology [22],
and (d) project feasibility. For a two-sided test, using
standard levels of statistical significance (alpha = 0.05), asample size of n = 21 complete data sets would have
80% power to detect a medium to large effect size
(Cohen’s d = 0.65) with 80% power, and a sample size
of n = 34 would be needed for a medium effect size
(Cohen’s d = 0.5).
The balanced two group, two period, two sequence,
double-blind, randomised crossover design with wash-
out period comparing treatment to control, ranks highly
in the hierarchy of designs. The analyses of the resultant
data under this AB/BA design may proceed using well
known statistical techniques (e.g. [23]).
Primary analyses will focus on nocturia episodes per
night and volume voided per night determined pre- and
post-treatment for the two conditions (melatonin, pla-
cebo) within each period. The experimental structure
therefore has a two by two fully repeated measures
structure. The design has been structured with a large
washout period and it is anticipated that there will be no
carryover effects on physiological and psychological out-
comes. This assumption will be tested. Period effects
should also be absent and this supposition will also be
tested and analysis will proceed to estimate treatment ef-
fects robust to any period effect (CROS analysis). It is
recognised that outcome data may be skewed for this
population and nonparametric or bootstrapped inference
will be used as appropriate. Analyses will proceed on an
Intent-to-Treat basis.
A missing data analysis will also be performed and
sensitivity of statistical conclusions to missingness will
be undertaken using standard imputation techniques.
Data integrity checks will be undertaken prior to infer-
ential analysis including a detailed graphical and sum-
mary statistics descriptive analysis. The statistician will
be masked to prevent ascertainment bias. All analyses,
and the reporting of analyses, will be undertaken in the
spirit and guidance of the CONSORT guidelines.
Monitoring
The TMG will consider safety/adverse effects, and assess
the possibility of futility. If issues of safety emerge, the
TMG will be empowered to request unblinded data. As
it deems necessary, the TMG will make recommenda-
tions to the sponsor on further study conduct, including
continuing, terminating, or modifying the trial. Early ter-
mination will result if unexpected adverse effects are
seen, or if the study is deemed futile, or if the beneficial
effect is so obvious that curtailment can occur.
Risk assessment
We anticipate no likely problems to result from use of a
low-dose of melatonin in a study of this nature. Nonethe-
less, a range of purported potential effects of melatonin
means the study includes three EDSS tests (pre-treatment
and at the end of each treatment period) to monitor
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also be captured as adverse events. Interim analysis will be
undertaken following the first treatment period and will
be submitted in a blinded report to the TMG (see above).
Monitoring at trial coordination centre
The trial co-ordination centre will undertake data entry
checks and consent form checks, and will screen for double
data entry, missing or unusual data values. Initiation and
first/screening recruitment visits will be undertaken.
Regulatory issues
Eudract Reference: 2012-004183-21 has been used for
UK competent authority (MHRA) forms in order to get
clinical trial authorization
Consent to enter the trial will be sought from each
participant only after a full explanation has been given, an
information leaflet offered and time allowed for consider-
ation. Signed participant consent will be obtained. The right
of the participant to refuse to participate without giving
reasons will be respected. After the participant has entered
the trial the clinician remains free to give alternative treat-
ment to that specified in the protocol at any stage if he/she
feels it is in the participant’s best interest, but the reasons
for doing so will be recorded. In these cases, the subjects
will remain within the trial for the purposes of follow-up
and data analysis. All subjects will be free to withdraw at
any time from study without giving reasons and without
prejudicing further treatment.
Where possible we will gain consent from study sub-
jects to approach partners, in order to invite them to
undertake qualitative interview regarding impact of noc-
turia on partners and gain their consent.
Confidentiality
Subject’s identification data will be required for the
registration process. The Trial Coordination Centre will
preserve the confidentiality of subjects taking part in the
trial and is registered under the Data Protection Act.
Access to the data
The Senior IT Manager (in collaboration with the CI) will
manage access rights to the data set. Prospective new users
must demonstrate compliance with legal, data protection
and ethical guidelines before any data are released. We an-
ticipate that anonymised trial data will be shared with
other researchers to enable prospective meta-analyses.
Data and all appropriate documentation will be securely
stored in archive for a minimum of 10 years after the
completion of the trial, including the follow-up period.
Sponsor
North Bristol NHS Trust will act as the Sponsor for this
trial. North Bristol NHS Trust holds standard NHSHospital Indemnity and insurance cover with NHS
Litigation Authority for NHS Trusts in England, which
apply to this trial. The trial may be subject to inspection
and audit by North Bristol NHS Trust under their remit
as Sponsor, the Trial Coordination Centre and other
regulatory bodies to ensure adherence to GCP.
Data Monitoring Committee
We aim to establish an independent Data Monitoring
Committee (DMC) comprising an independent chair
and two other independent members, to monitor accu-
mulating data during the course of the trial. All
personnel will have undertaken the mandatory Good
Clinical Practice (GCP) training.
Trial management
A Trial Management Group (TMG) has been appointed
and will be responsible for overseeing the progress of
the trial. The day-to-day management of the trial will be
co-ordinated through the MeNiMS Trial Coordination
Centre. All publications and presentations relating to the
trial will be authorised by the Trial Management Group.
Publication policy
The main forms of dissemination will be through the aca-
demic press and by lay summaries on websites and other
more accessible forms for patients. All participants will be
offered a lay summary of the main findings of the study.
This will be adapted for dissemination through public
channels. Dissemination to clinicians will be through pa-
pers in major urology and neurology journals and confer-
ences, workshops and presentations to national meetings.
Discussion
This study will evaluate whether melatonin reduces the
frequency of nocturia episodes in MS patients, and there-
fore whether ‘Circadin’ has the potential to reduce LUTS
and fatigue, and improve cognition and overall quality of
life. Nocturia and sleep disturbance are prevalent and
bothersome aspects of MS, and a safe and effective ther-
apy would be a valuable development. Melatonin may im-
prove either or both aspects, and has a good safety profile.
It is unlikely to affect necessary physiological function of
the lower urinary tract or the gut. Thus, it does not carry
the same concerns about side effects of drugs used to treat
overactive bladder syndrome, such as constipation or im-
paired bladder emptying.
The trial includes a wide range of outcome measures,
since the effect on nocturia and sleep quality may lead
to additional effects on cognitive function. Since this is a
clinical trial of an investigational medical product (using
an established drug but outside its licensed indication),
the measures also emphasises safety assessments, includ-
ing detailed assessment of MS severity.
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